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Abstract
Background: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to
inhibit the function of the epidermal growth factor receptor (EGFR). Lovastatin attenuated ligand-induced receptor
activation and downstream signaling through the PI3K/AKT pathway. Combining lovastatin with gefitinib, a potent EGFR
inhibitor, induced synergistic cytotoxicity in a variety of tumor derived cell lines. The vascular endothelial growth factor
receptor (VEGFR) and EGFR share similar activation, internalization and downstream signaling characteristics.
Methodology/Principal Findings: The VEGFRs, particularly VEGFR-2 (KDR, Flt-1), play important roles in regulating tumor
angiogenesis by promoting endothelial cell proliferation, survival and migration. Certain tumors, such as malignant
mesothelioma (MM), also express both the VEGF ligand and VEGFRs that act in an autocrine loop to directly stimulate tumor
cell growth and survival. In this study, we have shown that lovastatin inhibits ligand-induced VEGFR-2 activation through
inhibition of receptor internalization and also inhibits VEGF activation of AKT in human umbilical vein endothelial cells
(HUVEC) and H28 MM cells employing immunofluorescence and Western blotting. Combinations of lovastatin and a VEGFR-
2 inhibitor showed more robust AKT inhibition than either agent alone in the H28 MM cell line. Furthermore, combining
5 mM lovastatin treatment, a therapeutically relevant dose, with two different VEGFR-2 inhibitors in HUVEC and the H28 and
H2052 mesothelioma derived cell lines demonstrated synergistic cytotoxicity as demonstrated by MTT cell viability and flow
cytometric analyses.
Conclusions/Significance: These results highlight a novel mechanism by which lovastatin can regulate VEGFR-2 function
and a potential therapeutic approach for MM through combining statins with VEGFR-2 inhibitors.
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Introduction
Angiogenesis is an important physiological process during fetal
development and growth as well as in mature tissue remodeling
and repair [1]. For cancer expansion and dissemination, both
primary lesions and metastatic tumors must develop a new
vascular supply in order to survive [1]. Angiogenesis is tightly
regulated by balancing the activity of pro- and anti-angiogenic
factors [2]. Multiple pathways contribute to tumor angiogenesis
including vascular endothelial growth factor (VEGF), fibroblast
growth factor, and platelet-derived growth factor [2]. Based on the
central role of VEGF in tumor angiogenesis and growth, it has
emerged as a promising therapeutic target for angiogenesis
inhibition [3]. VEGF, a 35- to 45-kDa dimeric polypeptide, plays
a critical role in normal and pathologic angiogenesis [3]. The
VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and placental growth factors 1 and 2 [4]. The VEGF-A
gene, via alternative splicing, yields several isoforms, of which,
VEGF165 plays a critical role in tumor angiogenesis [3]. Tumor
cells secrete VEGF in response to many stimuli including hypoxia,
low pH, or cellular stress, which are prevalent in most solid tumors
[5].
VEGF exerts its biologic effect through interaction with
receptors present on the cell surface. These receptor tyrosine
kinases (RTK) include VEGFR-1 (Flt-1) and VEGFR-2 (KDR,
Flk-1), which are predominantly present on vascular endothelial
cells [6]. Both VEGFR-1 and VEGFR-2 have an extracellular
ligand binding domain, a transmembrane region, and a tyrosine
kinase domain [2,3]. In addition, VEGFR-3 (Flt-4) is expressed on
vascular and lymphatic endothelium while the neuropilin receptor
is expressed on vascular endothelium and neurons [2,3]. VEGFR-
2 is the main receptor responsible for mediating the proangiogenic
effects of VEGF in tumor-associated endothelium [7]. VEGF
binding to the extracellular domain of the VEGFR results in
dimerization and autophosphorylation of the intracellular tyrosine
kinases [8]. This activates multiple downstream proteins that play
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and stabilization of new blood vessels [8]. For example, VEGF
induces endothelial cell proliferation by activating the protein
kinase Ras-MEK-ERK pathway [8]. The pro-survival effects of
VEGF/VEGFR-2 are mediated by the PI3K/AKT pathway [8].
Recent studies indicate that VEGFR are also expressed by some
tumor cells and may represent an additional target [9].
Malignant mesothelioma (MM) is a highly aggressive tumor that
arises from the surface serosal cells of the pleura and, less
frequently, the peritoneum [10]. A strong link has been established
between exposure to asbestos and increased risk for MM [11].
Treatment of MM with surgery, chemotherapy, or radiation
therapy is rarely curative and median survival is in the range of
10–17 months [11]. Novel therapies for MM are needed. VEGF
up-regulation appears to play an important role in mesothelial cell
transformation. High levels of VEGF have been observed in the
serum of MM patients and elevated pleural effusion VEGF levels
are associated with poor survival in patients with MM [12]. VEGF
may also act in a functional autocrine loop capable of directly
stimulating the growth of MM cells [9]. MM cell lines express
elevated levels of both VEGF and the VEGFR-1 and 2 compared
with normal mesothelial cells [9]. VEGF activated these receptors
and increased proliferation of all MM cell lines examined [9].
Interestingly, significant vascularization is rarely exhibited in MM
suggesting that VEGF may play a key role in MM tumor
progression by primarily regulating tumor cell proliferation
suggesting VEGF/VEGFR as therapeutic targets in MM [10].
The rate-limiting step of the mevalonate pathway is the
conversion of HMG-CoA to mevalonate, which is catalyzed by
HMG-CoA reductase [13]. The mevalonate pathway produces
various end products that are critical for many different cellular
functions including cholesterol, dolichol, ubiquinone, isopenteny-
ladenine, geranylgeranyl pyrophosphate (GGPP), and farnesyl
pyrophosphate (FPP) [13]. Geranylgeranyl transferase and farnesyl
transferase use GGPP and FPP, respectively, for post-translational
modifications of a wide variety of cellular proteins including the
Ras, Rab, and Rho families [14,15]. These proteins regulate cell
proliferation, intracellular trafficking and cell motility and this
post-translational modification functions as a membrane anchor
critical for their activity [14,15]. Blockade of the rate-limiting step
of the mevalonate pathway by HMG-CoA reductase inhibitors
results in decreased levels of mevalonate and its downstream
products [16] and, thus, may have significant influences on many
critical cellular functions.
Malignant cells appear highly dependent on the sustained
availability of the end products of the mevalonate pathway [17].
The statin family of drugs are potent inhibitors of HMG-CoA
reductase that are widely used as hypercholesterolemia treatments
[16]. Mevalonate metabolites are required for the proper function
and localization of a number of downstream mediators of the
VEGFR-2 signaling cascade [3,18,19,20]. Proteins that require
FPP or GGPP posttranslational modifications play critical roles in
transducing these signals [3,18,19,20]. In our recent studies, we
have demonstrated that lovastatin treatment inhibits ligand-
induced activation of EGFR [18,21]. The mechanism by which
EGFR inhibition is mediated by lovastatin is novel and suggests a
previously unrecognized process controlling EGFR activity.
Due to the potential of lovastatin to target EGFR function and
its downstream signaling, we previously evaluated the effects of
combining lovastatin with the clinically relevant EGFR tyrosine
kinase inhibitor (TKI) gefitinib [22]. The combination of gefitinib
and lovastatin demonstrated significant co-operative cytotoxic
effects when cells were pretreated with lovastatin for 24 hrs. At this
time point, lovastatin demonstrated significant inhibition of EGFR
function [21]. We demonstrated co-operative cytotoxic effects with
this combination that was synergistic due to the induction of a
potent apoptotic response [21]. In this study, we evaluated the
potential of lovastatin to similarly inhibit VEGFR-2 function.
Furthermore, we evaluated the effects of lovastatin on endothelial
cell proliferation and survival as well as the effects of combining
lovastatin with VEGFR-TKIs on MM tumor cell viability as a
potential novel therapeutic approach.
Results
Lovastatin inhibits internalization and degradation of the
VEGFR-2
Previous studies have demonstrated that ligand binding to
VEGFR-2 leads to receptor dimerization and autophosphoryla-
tion [8]. Autophosphorylation leads to the activation of its
downstream signaling cascades and receptor internalization and
degradation in lysosomes [8]. In this study, we evaluated the effect
of lovastatin on VEGFR-2 internalization and degradation in
VEGF treated HUVEC cells. Localization of VEGFR-2 was
visualized by immunofluorescence staining. HUVEC cells were
exposed to solvent control with or without treatment of 50 ng/ml
VEGF165 for 30 min. In un-stimulated HUVEC cells, VEGFR-2
showed a dispersed staining pattern on the cell surface. With the
addition of VEGF165, however, VEGFR-2 showed a distinct
punctate intracellular staining pattern indicating efficient inter-
nalization of this receptor [23] in HUVEC (Figure 1A). Treatment
of HUVEC with 2 mM lovastatin for 24 hrs showed a similar
diffuse surface-staining pattern for VEGFR-2 as control cells.
Addition of 50 ng/ml of VEGF165 for 30 min in lovastatin treated
cells significantly reduced the punctuate intracellular staining
pattern shown in control VEGF165 treated cells but displayed a
similar diffuse staining pattern to control un-stimulated cells
(Figure 1A).
To further examine whether lovastatin is regulating the
internalization of the VEGFR ligand complex, we performed the
Pinpoint Cell Surface Protein Isolation method that specifically
labels and isolates proteins found on the cell surface. Cell surface
proteins were biotinylated and isolated using immobilized avidin,
prior to Western blotting with the VEGFR-2 antibody. As shown
in Figure 1B, untreated HUVEC were found to have significant
levels of VEGFR-2 expressed on the cell surface. As expected,
stimulation with VEGF165 at 50 ng/ml for 30 min decreased the
levels of VEGFR-2 on the cell surface (Figure 1B). In 2 mM
lovastatin treated cells for 24 hrs, lower levels of surface expression
of VEGFR were evident. This decrease may be the result of the
inhibition of intracellular transport that is regulated in part by the
geranylgeranylated rab protein family. Ligand stimulation did not
affect VEGFR-2 surface expression in lovastatin treated cells
indicative of inhibition of internalization. In untreated cells, actin
was readily detected in the avidin pull downs while lovastatin
treated cells had significantly lower levels (Figure 1B). These results
suggest that in lovastatin treated HUVEC; surface protein binding
of actin was inhibited. These results correspond well with recent
studies that demonstrate a role for the actin cytoskeleton in the
multi-step process of receptor internalization [24,25].
Internalization of ligand bound VEGFR-2 often leads to its
degradation in lysosomes as a way to attenuate its signal. To
determine the effect of lovastatin on VEGFR-2 degradation, we
performed Western blot analyses of total cellular protein extracted
from VEGF165 stimulated HUVEC and H28 MM cells with or
without lovastatin treatments. In HUVEC, the basal levels of
VEGFR-2 were unchanged with or without 0.5, 1 and 5 mM
lovastatin treatments for 24 hrs (Figures 1C and D). Control
Lovastatin Inhibits VEGFR
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demonstrated a significant decrease in VEGFR-2 protein levels
indicating efficient degradation of ligand bound VEGFR-2 in
these cells (Figures 1C and D). Treatment of HUVEC with 0.5, 1
and 5 mM lovastatin for 24 hrs attenuated the effect of VEGF165
addition on VEGFR-2 degradation as the levels of VEGFR-2 were
significantly elevated in lovastatin-treated in comparison to control
cells (Figures 1C and D). Ponceau Red staining of the membranes
confirmed equal loading between samples and the area of the blot
shown corresponds to the area where VEGFR-2 migrated. These
results indicate that lovastatin treatment inhibits ligand-induced
internalization and degradation of VEGFR-2 in HUVEC and
H28 MM cells.
Based on lovastatin’s ability to inhibit ligand-induced internal-
ization of VEGFR-2, we further evaluated the effect of lovastatin
treatment on the signaling cascades triggered by VEGFR-2
activation. The PI3K/AKT signaling pathway plays a significant
role in cell survival responses mediated by VEGFR-2 [3]. Ligand
bound VEGFR-2 activates PI3K that phosphorylates the phos-
pholipid PIP2 resulting in the accumulation of PIP3 that in turn
activates AKT [26]. Serum starved H28 MM derived cell line and
HUVEC cells were treated with 0, 1, 10 and 25 mM lovastatin for
24 hrs followed with 50 ng/ml VEGF165 stimulation for 30 min.
The functional activation of this pathway was evaluated by
Western blot analysis, employing phospho-specific antibody
recognizing the active form and control antibody for total AKT.
Lovastatin treatment inhibited activation of AKT in a dose
dependent manner that was readily detectable at the 1 mM dose in
HUVEC but was less efficient in inhibiting AKT activation in H28
cells (Figure 2). There are a wide variety of AKT targets that
regulate its effects on protein translation, proliferation and cell
survival. These targets include ribosomal S6 kinase (S6K1) and
eukaryotic translation initiation factor 4E (eIF4E) that regulate
translation [27]. We evaluated the effects of lovastatin on ligand-
induced activation of these proteins in our 2 model cell lines.
Western blot analysis determined the effects of 0, 1, 10 and 25 mM
lovastatin treatment for 24 hrs with 30 min 50 ng/ml VEGF
addition on these AKT targets. Lovastatin treatment significantly
inhibited phosphorylation of S6K1 (not detected in HUVEC) and
4EBP1 in a dose dependent manner (Figure 2). Activated
phosphorylated AKT, S6K1 and 4EBP1 were not detected in
serum starved control cells (data not shown). These results
demonstrate the ability of lovastatin to readily inhibit VEGF
induced AKT activation in these cell lines.
Lovastatin induces cytotoxicity of HUVEC and MM Cells
Due to the regulation of cell viability by the AKT pathway, we
evaluated the effects of lovastatin treatment on HUVEC and H28
cell viability. Cell viability assays based on trypan blue exclusion
cell counts of HUVEC and H28 cells were evaluated at 72 hrs.
The effect on cell viability of exogenous addition of VEGF165 was
included in this study to determine the role of this pathway in
regulating lovastatin-induced cytotoxicity. Treatment with lova-
statin alone at 0.5, 1, 2 and 5 mM concentrations resulted in a
dose-dependant decrease in the percentage of viable cells
Figure 1. Lovastatin treatment inhibits VEGFR-2 internaliza-
tion. A, VEGFR-2 internalization in HUVEC was evaluated by immuno-
fluorescence. HUVEC were treated with solvent control or 2 mM
lovastatin for 24 hrs in serum-free media followed by 30 min of
stimulation with VEGF165. Immunofluorescence staining of HUVEC
revealed a punctate intracellular staining pattern upon VEGF165 ligand
binding in the control but not in cells treated with 2 mM lovastatin. The
data is typical of 3 independent experiments. B, Cell Surface Pinpoint
Protein Isolation revealed a decrease in VEGFR-2 on the surface of
control HUVEC upon VEGF stimulation but not with 2 mM lovastatin
treatment. Actin was readily pulled down in control cells but not in
lovastatin treated HUVEC indicating a lack of association of surface
proteins with actin in lovastatin treated cells. C and D, Western blot
analysis reveals that VEGFR-2 receptor levels decrease with 30 min of
stimulation with VEGF165 stimulation in control HUVEC and H28 cells
respectively. Lovastatin treatments of 0.5, 1 and 5 mM inhibited VEGFR
degradation in a dose dependant manner. The data is typical of at least
3 independent experiments and the membranes were stained with
Ponceau Red to visualize total protein loading.
doi:10.1371/journal.pone.0012563.g001
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control cells (Figures 3A and B). The addition of VEGF165 to
lovastatin treated cells inhibited lovastatin induced cytotoxicity at
the low 0.5 and 1 mM lovastatin doses but this compensatory effect
was reduced or eliminated at the higher 2 and 5 mM lovastatin
treated cells (Figures 3A and B). The percentage of apoptotic
HUVEC 72 hrs (Figure 3B) post-treatment was assessed using
propidium iodide flow cytometry to study the effects of lovastatin
in inducing apoptosis. The control cells showed a sub-G1 peak in
the DNA histogram that is characteristic of apoptotic cells
representing approximately 26% of cells analyzed, while addition
of VEGF165 resulted in a reduction of apoptotic cells to
approximately 13%, highlighting the role of VEGF in promoting
HUVEC cell survival. At a dose of 1 mM and 2 mM, lovastatin
induced significant apoptosis above the levels of that observed in
the control cells. However, for the 1 mM lovastatin concentration,
VEGF165 was still able to able to diminish the apoptotic effects of
lovastatin on HUVEC but with the higher 2 mM lovastatin dose,
addition of VEGF165 had no significant affect on the induction of
apoptosis (Figure 3B). The cell viability and flow cytometric
analyses show the ability of lovastatin to induce a potent apoptotic
response in HUVEC that at lower doses can be rescued by VEGF
but not at the higher doses relevant for use of lovastatin as an anti-
cancer therapeutic [28,29].
Lovastatin affects cytoskeleton organization and RhoA
Activity
Actin cytoskeletal organization is known to play a significant
role in the internalization and intracellular trafficking of RTK
including VEGFRs. RhoA and cdc42 regulate actin cytoskeleton
architecture and are activated by VEGF to control cell shape and
motility [23]. RhoA and cdc42 are GGPP modified proteins whose
function can be inhibited by lovastatin treatment [15]. Lovastatin
induced dramatic changes in the actin cytoskeletal organization of
HUVEC. Treatment with 0.5, 2 and 5 mM lovastatin for 24 hrs,
resulted in a significant reduction of F-actin fibers stained with
rhodamine-conjugated phalloidin and these fibers appeared
disorganized (Figure 4A). In HUVEC and H28 MM cells,
treatment with 0.5, 1 and 5 mM lovastatin for 24 hrs induced a
dramatic up-regulation of both rhoA and cdc42 protein levels
(Figure 4B). Cyclin D1 is a regulator of cell cycle progression and is
up-regulated by a wide variety of cellular signaling pathways
including rhoA activation [30]. The significant increase of rhoA
protein levels did not result in up-regulation cyclinD1 protein
levels but were reduced with lovastatin treatment of HUVEC and
H28 cells (Figure 4B). Furthermore, employing a colorimetric
rhoA activation assay, we determined the effect of lovastatin on
VEGF165 induced rhoA activation in HUVEC and H28 cells.
Serum starved cell extract represent inactive levels of rhoA while
0.2M GTP loaded extract represents fully active rhoA. As
expected VEGF stimulation induced rhoA activity to approxi-
mately 60% of the GTP loaded activity. Lovastatin (10 mM,
24 hrs) inhibited VEGF165 induced rhoA activation in both
HUVEC and H28 cells while co-administration of mevalonate
(100 mM) and GGPP (10 mM) reversed the inhibitory effects of
lovastatin (Figure 4C). These results demonstrate that lovastatin-
induced rhoA is inactive likely due to the lack of GGPP
modification.
Inhibition of the VEGFR augments lovastatin-induced
apoptosis
Our previous studies have demonstrated that the combination
of lovastatin and EGFR-TKI have resulted in synergistic
cytotoxicity in a variety of human cancer derived cell lines [21].
Other studies have demonstrated the utility of combining EGFR-
TKI with downstream inhibitors of the AKT pathway including
rapamycin. Mammalian target of rapamycin (mTOR) plays a
central role in regulating AKT driven translation initiation by
regulating S6K1 and 4EBP1 activity [31]. Rapamycin has limited
clinical activity due to a feedback loop that activates AKT and
acquired resistance [31] suggesting that lovastatin may represent a
novel therapeutic approach to target this pathway and enhance
RTK-TKI activity. In this study, we evaluated the ability of
rapamycin or lovastatin to augment the effects of the VEGFR-2
inhibitor KRN633. The H28 MM cell line had a relatively weak
response to lovastatin-induced AKT inhibition. H28 cells express
both VEGF and VEGFR-2. By Western blot analysis of activated
AKT and its downstream targets S6K1 and 4EBP1, KRN633 and
rapamycin treatments alone had minimal effects on the activation
of these proteins. The combination of these agents showed
enhanced inhibition of this pathway (Figure 5). In contrast,
lovastatin treatment alone inhibited AKT, S6K1 and 4EPB1
phosphorylation and the combination of lovastatin and KRN633
induced a dramatic inhibition of the AKT pathway in this MM
derived cell line (Figure 5).
We further evaluated the combination of lovastatin and
VEGFR-2 TKI on tumor cell cytotoxicity in HUVEC and MM
cells. Utilizing MTT analysis and propidium iodide flow
cytometry, we investigated the effects of combining two different
VEGFR-TKIs with lovastatin on the viability of the H28 and
H2052 MM derived cell lines and HUVEC. KRN633 inhibits
VEGFR 1, 2 and 3 with similar kinetics while ZM323881 is highly
selective for VEGFR-2 [32,33]. With both MM derived cell lines
and in HUVEC, increases in the concentration of the VEGFR-
TKIs, KRN633 and ZM323881, resulted in a dose dependent
decrease of MTT activity (Figure 6A). The pre-treatment of either
5 mMo r1 0mM lovastatin for 24 hrs prior to the addition of 0–
25 mM concentrations of the VEGFR-TKIs for 48 hrs resulted in
co-operative cytotoxicity in both MM cell lines and HUVEC
treated with either VEGFR-TKI (Figure 6A). The use of the
Figure 2. Lovastatin inhibits VEGF induced activation of AKT
and its downstream targets. Cell lysates from HUVEC and H28 cells
were collected following control, 1, 10 and 25 mM 24 hr lovastatin
treatments in serum-free media with 50 ng/ml 30 min VEGF165
stimulation. Phosphorylation level of AKT decreased with lovastatin
treatment in a dose dependent manner. Expression level of total AKT
was assayed as the loading control. Phosphorylation levels of S6K1 and
4EBP1 also decreased with lovastatin treatment in a dose dependent
manner. Phosphorylated S6K1 in HUVEC cells was not detectable (ND).
Expression levels of total S6K1 and 4EBP1 were assayed as the loading
control.
doi:10.1371/journal.pone.0012563.g002
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allowed for the determination of the effects of the combination of
the lovastatin and VEGFR-TKIs (Figure 6B). CI values of ,1, 1,
and .1 are indicative of synergism, additive effect, and
antagonism, respectively. The H28 MM cell line at the
therapeutically relevant 5 mM dose of lovastatin resulted in a CI
value of 0.58 for the combinatorial treatment of lovastatin and
ZM323881, but the combination of lovastatin and KRN633
obtained a CI value of 1 (Figure 6B). The H2052 MM cell line and
HUVEC had CI values of less than one for both VEGFR-TKIs.
Figure 3. VEGF can partially rescue the cytotoxic and apoptotic effects of lovastatin. A and B, HUVEC and H28 cell proliferation was
measured with a cell viability assay following either control or 0.5–5 mM 72 hr lovastatin treatments with or without 50 ng/ml VEGF165. VEGF165
stimulated control cells to proliferate, however, higher doses of lovastatin inhibited the proliferative effects of VEGF165. The data were normalized to
untreated (media alone) cells (representing 100%) and are representative of 4 independent experiments. C, Apoptosis was measured using flow
cytometric analysis of HUVEC following either control or 1 and 2 mM 72 hr lovastatin treatments with or without 50 ng/ml VEGF165. Results
demonstrated that lovastatin was preventing the apoptotic inhibitory effects of VEGF165 at higher doses (2 mM). The data is typical of 2 independent
experiments.
doi:10.1371/journal.pone.0012563.g003
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TKIs consistently induced synergistic cytotoxicity in MM and
HUVEC cells.
To determine if this combination based approach resulted in
enhanced apoptosis, we assessed MM cells treated with 5 mMo r
10 mM of the VEGFR-TKIs alone or in combination with 5 mM
lovastatin using the same experimental conditions as above. In
both cell lines, with both VEGFR-TKIs tested, the combination
with 5 mM lovastatin with 5 mM and 10 mM of the VEGFR-TKIs
induced a more potent apoptotic response than either agent alone.
Figure 4. Lovastatin treatment results in actin disorganization and inhibits VEGF induced rhoA activation. A, Actin cytoskeletal
organization was visualized using rhodamine-conjugated phalloidin following 24 hr 0.5, 2 and 5 mM lovastatin treatments of HUVEC. Staining
revealed a lovastatin induced decrease in F-actin fibers along with a disorganized pattern. The data is typical of 3 independent experiments. B,
Western blot analysis of various downstream targets of the VEGF receptor in HUVEC and H28 cells. Cell lysates were collected following 24 hr
lovastatin treatment in serum-free media and either control or 30 min VEGF165 stimulation. Total levels of RhoA and Cdc42 increase with increasing
concentrations of lovastatin irrespective of VEGF165 stimulation. Total levels of cyclin D1 drop as the concentration of lovastatin is increased. C, Rho A
activation assays. Serum starved HUVEC and H28 cells were treated with 10 mM lovastatin, 100 mM mevalonate and 10 mM GGPP alone and in
combination as indicated for 24 hrs. Cells were stimulated with VEGF for 30 min as indicated and assayed for rhoA activity employing the RhoA G-
LISA kit that quantifies activated GTP loaded rhoA through colorimetric detection of rhoA bound to Rho-GTP-binding protein.
doi:10.1371/journal.pone.0012563.g004
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KRN633 are shown (Figure 6C) and demonstrate a significant
increase in apoptosis of the cells when the treatments were
combined. Lovastatin treatment (5 mM) induced an apoptotic
response that was significantly enhanced in combination with
10 mM KRN633 treatments (Figure 6C). Thus, the synergistic
cytotoxicity observed with the combination of lovastatin and
VEGFR-TKIs in MM cells is accompanied by a potent apoptotic
response.
To further demonstrate the role of VEGFR-2 as a target of
these VEGFR-TKIs in the synergistic cytotoxicity observed in
combination with lovastatin in MM cells, we specifically targeted
the expression of VEGFR-2 employing short inhibitory RNA
sequences (siRNAs). Employing the MTT cell viability assay, we
demonstrated that while the siControl treatments (50 nM 48 hrs,
followed by 48 hrs lovastatin treatment) had no effect on lovastatin
treatments (1 and 5 mM) compared to reagent alone, siVEGFR-2
(50 nM 48 hrs, followed by 48 hrs lovastatin treatment) signifi-
cantly enhanced lovastatin-induced cytotoxicity in H2052 and
H28 MM cells (Figure 6D). Western blot analysis confirmed the
specificity of the siRNAs employed as siVEGFR-2 but not
siControl targeted VEGFR-2 expression at 48 and 96 hr
treatments (Figure 6D).
Discussion
In our previous study, we demonstrated that the targeting of
HMG-CoA reductase, which results in mevalonate depletion [16],
can inhibit the function of the EGFR [21]. Furthermore,
combining lovastatin with gefitinib, an EGFR-TKI, induced
apoptotic and cytotoxic effects that were synergistic. This was
demonstrated in several types of tumor cell lines and potentially
involved the PI3K/AKT pathway [21]. The mechanisms
regulating the inhibitory effects of lovastatin on EGFR function
and the synergistic cytotoxicity in combination with gefitinib are
currently not known. These findings suggest that mevalonate
pathway inhibitors and receptor TKI may represent a novel
combinational therapeutic approach in a variety of human
cancers. The VEGFR and the EGFR are both members of
RTK family that share similar activation, internalization and
downstream signaling characteristics [3,35]. Therefore, targeting
the mevalonate pathway may have similar inhibitory effects on
VEGFR and may also enhance the activity of VEGFR-TKI.
VEGFR, particularly VEGFR-2, play important roles in regulat-
ing angiogenesis by promoting endothelial cell proliferation,
survival and migration [7]. VEGF and VEGFR are also expressed
by some tumor cells, like MM, acting in a functional autocrine
loop capable of directly stimulating the growth and survival of
MM cells [9].
In this study, we have shown lovastatin does indeed inhibit
ligand-induced VEGFR-2 activation through inhibition of recep-
tor internalization resulting in diminished AKT activation in
HUVEC and MM cells. Lovastatin treatment re-organized the
actin cytoskeleton, inhibited proliferation and induced apoptosis of
HUVEC at therapeutically relevant doses (,5 mM) [29] despite
addition of exogenous VEGF. AKT activation, which mediates
cell survival, along with its downstream targets S6K1 and 4EBP1
were significantly inhibited by lovastatin treatment. Combining
lovastatin with VEGFR-TKIs also induced synergistic cytotoxicity
of HUVEC cells. Due to their role in promoting tumor
neovascularization, inhibiting the function of VEGF and VEGFR
has been the focus of a number of therapeutic approaches [1]. The
limited clinical responses associated with these agents have been
associated with their ability to promote disease stabilization and
rarely induce tumor regression [1,36]. Thus, agents that can co-
operate and enhance the activity of VEGFR-TKI, like lovastatin,
may increase their therapeutic activity.
MM is a highly aggressive tumor that is rarely curative and
median survival is in the range of 10–17 months [11], therefore,
novel therapies for MM are needed. Elevated levels of circulating
and serousal VEGF in MM patients and the expression of VEGF
and VEGFR on MM cells that can drive their proliferation and
enhance their survival [9] has led to the evaluation of VEGFR
targeted therapies. Bevacizumab, a monoclonal antibody against
the VEGF, which is approved for the treatment of colon cancer, in
combination with chemotherapy, failed to significantly affect
outcome to chemotherapy treatment alone [37]. Various VEGFR-
TKI employed a single agents also failed to demonstrate clinical
utility in MM patients [37]. As like HUVEC, MM cells also
depend on VEGFR signaling, we also examined the effect of
lovastatin alone and in combination with VEGFR-2 TKI on MM
cell viability. Combining 5 mM lovastatin treatments with two
VEGFR-2 inhibitors in the H28 and H2052 mesothelioma derived
cell lines demonstrated synergistic cytotoxicity through the
induction of a potent apoptotic response. These results highlight
a novel mechanism regulating VEGFR-2 function and a potential
novel therapeutic approach for MM.
Inhibition of HMG-CoA reductase has been evaluated as an
anti-cancer therapeutic approach owing to its ability to inhibit
tumor cell proliferation, induce tumor specific apoptosis and
inhibit cell motility and metastasis in several tumor models [38–
41]. A number of Phase I Clinical trials evaluating the efficacy of
high doses of lovastatin failed to demonstrate significant anti-
tumor activity [29]. The tumor types evaluated in these studies did
not include those that we identified as being highly sensitive to
lovastatin-induced apoptosis, including head and neck squamous
Figure 5. Lovastatin in combination with VEGFR-2 TKIs inhibits
ligand induced activation of AKT, S6K1 and 4EBP1. Control cells
were serum starved for 24 hr followed by 2 hr treatments with either
10 mM KRN633, 10 nM rapamycin, 5 mM lovastatin or their combina-
tions. All cells were then lysed after stimulation with 50 ng/ml VEGF165
for 30 min. Results demonstrated that lovastatin in combination with
KRN633 induced the most significant decrease in phosphorylation
status of all three proteins in H28 cells. Expression levels of total AKT,
S6K1 and 4EBP1 were assayed as loading controls.
doi:10.1371/journal.pone.0012563.g005
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12563Figure 6. Combining lovastatin with VEGFR-2 TKIs induces synergistic cytotoxicity in MM cells and HUVEC. A, Evaluating the cytotoxic
effects of treatment of lovastatin in combination with VEGFR-TKI on MM cell lines H28 and H2052 and HUVEC employing MTT Assays. The VEGFR-2-
TKIs KRN633 and ZM323881 at doses of 1–25 mM were evaluated alone or in combination with 5 and 10 mM lovastatin. MTT data were normalized to
untreated (media alone) cells (representing 100%) and is typical of 2 independent experiments. B, Isobologram analyses of the combination of 5 mM
lovastatin and VEGF receptor inhibitor. MTT50 values were determined for 72 hr lovastatin and 48 hr VEGF receptor inhibitor treatments. MTT50
values are represented on the axes. The concentration of VEGF receptor inhibitor that demonstrated MTT50 with 5 mM lovastatin was plotted.
Combination-Index (CI) was determined with CI,1, CI=1, and CI.1 as synergism, additive effect, and antagonism, respectively [34]. C, Apoptosis was
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clinical evaluation of lovastatin in recurrent head and neck
squamous cell carcinomas and cervical carcinoma patients was
undertaken by our group. Although no tumor regressions were
observed, 23% of patients exhibited stable disease [28]. Taken
together, the most effective use of lovastatin and VEGFR-TKI
would be as part of a combined modality approach.
Due to the potential for mevalonate metabolite depletion to
functionally alter the VEGFR signaling pathway, HMG-CoA
reductase and VEGFR targeted therapies may be associated. This
study has shown that the combination of lovastatin with two
VEGFR-TKIs induced significant co-operative cytotoxicity in
both MM cell lines tested. More detailed isobologram analysis
demonstrated that this enhanced cytotoxic response was synergis-
tic. These results suggest the potential of combining these two
therapeutic approaches. The inhibition of mevalonate synthesis
and the depletion of one or more mevalonate metabolites is the
mechanism regulating this phenomenon. The combination of
statins and VEGFR-TKI represents an attractive therapeutic
approach as clinical trials have shown a different spectrum of
toxicities with these agents [29,36]. In a recent manuscript, we
have demonstrated similar inhibition of EGFR function by
lovastatin in squamous cell carcinoma cells [42]. While in vivo
murine tumor models evaluating the efficacy of statins have been
employed, differences in drug metabolism between species and
lack of target validation in many studies suggests the potential of
off target effects playing a role in statin response [43,44,45]. To
circumvent these issues, we evaluated the BR.21 NCIC-CTG
Phase III clinical trial of the EGFR-TKI inhibitor tarceva as a
single agent in non-small cell lung carcinoma patients [46]. In this
trial, patients on erlotinib that were also taking statins to treat
hypercholesterolemia had a trend to better outcomes than patients
on erlotinib alone [42]. These studies have led to a Phase I/II
clinical trial at our institute combining cerivastatin and erlotinib
that is currently accruing patients (ClinicalTrials.gov Identifier:
NCT00966472). Similar data for statin usage in VEGFR-TKI
treated MM patients were not available due to the lack of a
sufficient patient population for analysis. The ability of lovastatin
to inhibit both EGFR and VEGFR function is intriguing and
requires further study to elucidate its underlying mechanism. This
suggests the potential for HMG-CoA reductase inhibition to affect
the activity of a number of RTK potentially through a similar,
novel and as yet uncharacterized mechanism.
Ethical Statement
Not applicable with respect to this study.
Materials and Methods
Tissue Culture
Human Umbilical Vein Endothelial Cells (HUVEC) (Clonetics,
lot 2F1276, Walkersville, MD) were maintained in EGM-2 media
supplemented with 2% fetal bovine serum provided in the EGM-2
Single Quot Kit Supplements and Growth Factors (Lonza, East
Rutherford, NJ). The human mesothelioma lines, NCI-H28 and
NCI-H2052, were obtained from the American Type Culture
Collection (ATCC, Rockville, MD) and maintained in HyQ
DMEM/High Glucose (HyClone, Logan, Utah) supplemented
with 10% fetal bovine serum (Medicorp, Montreal, QC). The cell
lines used in this study were exposed to solvent control or
lovastatin (provided by Apotex, Mississauga, ON; diluted from a
10mmol/L stock in ethanol), or human recombinant VEGF165
(provided by National Cancer Institute, Rockville, MD; reconsti-
tuted to a 50 mg/ml stock in deionized water) at a concentration
of 50 ng/ml. The mesothelioma cell lines were exposed to solvent
control or VEGFR-2 Inhibitor V, ZM323881, or VEGFR-TKI
III, KRN633 (Calbiochem; both reconstituted to a 1mmol/L stock
in DMSO). The siRNA oligonucleotides used in this study were
purchased from Dharmacon (Boulder, CO). siControl: siGEN-
OME non-targeting siRNA, siVEGFR-2: siGENOME SMART-
pool human KDR. Transfection procedures were performed with
DharmaFECT-4 reagent (Dharmacon) in both H28 and H2052
cells according to the manufacturer’s protocols. Cells were grown
on 6-well plates or 96-well plates and transfected with 50 nM of
the siRNAs. After two days incubation, cells were treated with
media or 10 mM lovastatin for another 48 hrs. The cytotoxic
effects of lovastatin remained consistent in all three cell lines
throughout the course of these experiments.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assay (MTT Assay)
In a 96-well, flat-bottomed plate (Fisher, Mississauga, ON),
,7500 cells/150 ml of cell suspension were used to seed each well.
The cells were incubated overnight to allow for cell attachment
and recovery. Following a 48- or 72-hr treatment of lovastatin,
ZM323881, KRN633, or a combination of lovastatin and a
VEGFR-TKI, 42 mL of a 5 mg/ml solution in PBS of the MTT
substrate (Sigma) was added and incubated for up to one hr at
37uC. The resulting blue-brown formazan precipitate formed was
solubilized by the addition of 84 mL of a 0.01M HCl/10%SDS
(Sigma) solution and incubated for 8 hrs at 37uC. The plates were
then analyzed on a Dynex Technologies MRX Microplate Reader
at 570 nm using the Revel software (Dynex Technologies,
Chantilly, VA) to determine the absorbance of the samples.
Treatments were performed in replicates of six and the means
expressed as the percent viability relative to the untreated control
(100% viable). Statistical analysis: Combination Index (C.I.) was
determined by the method of Chou and Talalay as previously
described [34]. P values were determined by standard paired T-
test evaluations.
Cell Viability Assay
In a 6-well flat-bottomed plate (Fisher), ,500000 HUVEC were
used to seed each well. The cells were incubated overnight to allow
for cell attachment and recovery. Following 72 hr treatment using
solvent control or lovastatin in the presence or absence of 50 ng/
ml VEGF165, the cells were trypsinized and collected. The number
of viable cells in 500 ml of each sample was subsequently counted
on the Beckman Coulter Vi-Cell-XR Cell Viability Analyzer
measured using flow cytometry analysis of H2052 MM cells following either control or combinations of 10 mM KRN633 with 5 mM lovastatin
treatments. The percentage of apoptotic cells is shown in the upper left quadrant of each histogram. Results demonstrated that lovastatin in
combination with KRN633 induced a potent apoptotic response in these cells. The data is typical of 2 independent experiments. D, H28 or H2052 cells
were transiently transfected with 50 nM control (siControl) or VEGFR-2 (siVEGFR-2) siRNA oligonucleotides for 48 hrs. Cells were then treated with
media or 1 and 5 mM lovastatin with fresh 50 nM siRNAs for an additional 48 hrs and analyzed for cell viability using the MTT assay. * P,0.001
comparing siControl to siVEGFR-2 in lovastatin treated cells as determined by paired T-test analysis. Total protein extracts in H2052 and H28 cells
were analyzed by Western blotting for VEGFR-2 and actin following 48 and 72 hrs treatments with 50 nM of siControl and siVEGFR-2 siRNAs.
doi:10.1371/journal.pone.0012563.g006
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were normalized to the untreated control.
Propidium Iodide Flow Cytometry
In 10-cm plates (Fisher), ,3.5610
5 mesothelioma cells or
,5610
5 H U V E Cw e r eu s e dt os e e de a c hp l a t e .T h ep l a t e sw e r e
incubated overnight to allow for cell attachment and recovery.
The HUVEC were treated with solvent control or lovastatin, in
t h ep r e s e n c eo ra b s e n c eo f5 0n g / m lV E G F 165 for 72 hrs. The
mesothelioma cells were treated with solvent control or
lovastatin. Following a 24-hour pre-treatment with lovastatin
alone, solvent control or VEGFR Inhibitor (KRN633 or
ZM323881) was added for an additional 48 hrs. After the
desired treatment length, the media, PBS wash and trypsinized
cells were collected in the same 50 mL conical tube. The
collected cells were fixed with 80% ethanol and incubated at
220uC for a minimum of 24 hrs. The cells were washed once
then resuspended in staining buffer containing 50 mg/ml
propidium iodide (Sigma) and 100 mg/ml RNaseA (Invitrogen,
Carlsbad, CA). Ten thousand cells were evaluated using the
Beckman Coulter Epics XL Flow Cytometer and the percentage
of cells in pre-G1 phase was determined using the ModFit LT
program (Verity Software House, Topsham, ME).
Western Blot Analysis
Total cellular protein was extracted using a buffer that consisted
of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.25% sodium
deoxycholate (Sigma), 1% IgePal, 0.1% SDS (Sigma), 1 mM
EDTA, 5 mM sodium fluoride (Sigma), 1 mM sodium orthova-
nadate (Sigma), and protease inhibitor cocktail (Sigma; diluted
from a 106stock). Approximately 100 mL of extraction buffer was
used per plate. Total protein was quantified with the BCA Protein
Assay Reagents (Pierce, Nepean, ON) using bovine serum albumin
(Sigma) for the standard. Protein extracts representing 50 to
100 mg total protein were separated on SDS-PAGE gel using the
BioRad Mini Protean 3 System (Bio-Rad Laboratories, Hercules,
CA) and electro-blotted onto Hybond P PVDF membranes
(Amersham, Piscataway, NJ). Membranes were blocked in 5%
skim milk powder in PBS/0.02% Tween (Sigma) for an hour at
room temperature. Primary antibody, diluted in 5% skim milk
powder in PBST, was incubated with the membrane overnight at
4uC. The primary antibodies used were specific for VEGFR-2,
RhoA, cdc42, cyclinD1 (Santa Cruz Biotechnologies, Santa Cruz,
CA); phospho-AKT, AKT, phospho-S6K1, S6K1, phospho-
4EBP1, 4EBP1 (Cell Signaling Technology, Danvers, MA); and
actin (Sigma). The peroxidase-conjugated AffiniPure Goat Anti-
mouse/rabbit IgG (Jackson ImmunoResearch, West Grove, PA)
secondary antibodies were applied at a 1:5000 dilution and the
peroxidase-labeled Affinity Purified Antibody to goat IgG (KPL)
secondary antibody was applied at a 1:1000 dilution in 5% skim
milk powder in PBST and incubated for a minimum of an hour at
room temperature then processed for detection with the Super-
signal West Pico Chemiluminescent Substrate (Pierce), using the
Gene GNOME Imager and Genesnap Imaging Software
(Syngene, Frederick, MD). After the desired exposure was
obtained, the membrane was stained with Ponceau Red (Fisher)
to ensure equal loading of the samples. Membranes were stripped
using Restore Western Stripping Buffer (Pierce, Nepean, ON) to
allow for a second probing.
Pinpoint Cell Surface Protein Labeling
The Pinpoint Cell Surface Protein Isolation Kit (Pierce) was
used to identify and isolate cell surface proteins following the
manufacturer’s instructions. In brief, control or 24 hrs lovastatin
treated HUVEC cells were stimulated with or without 50 ng/ml of
VEGF for 30 min. Cells were then washed with ice-cold PBS and
surface proteins were biotinylated and isolated using immobilized
avidin, prior to Western blot analysis of VEGFR-2 and actin levels
as described above.
Phalloidin Staining/Immunofluorescence
In a 6-well flat-bottomed plate (Fisher), glass cover slips
(Fisher) were placed into each well and ,250000 cells were
used to seed each well. The cells were incubated overnight to
allow for cell attachment and recovery. Following a 24 hr
treatment of solvent control or lovastatin in serum-free media,
the HUVEC cells were treated with recombinant human-
VEGF165 for 30 min prior to fixation. The cells were
subsequently washed with PBS then fixed with 4% parafor-
maldehyde (Sigma) buffered in PBS for 15 min at 37uCa n d
stored in PBS at 4uC. To visualize actin cytoskeletal
architecture, 100 mL of a 1 ng phalloidin-rhodamine conjugate
in PBS was used to treat each cover slip containing the attached
HUVEC cells for 15 min in the dark. Prior to immunofluores-
cence staining, the cells were permeabilized with
PBS+0.2%Triton X-100 (Sigma) for 15 min. The cells were
blocked for 30 min with PBS+3%FBS then incubated with the
VEGFR-2 antibody at a dilution of 1:50 in PBS+3%FBS for an
hr. The cells were then blocked with PBS+5% chicken serum
(Sigma) for 30 min. Following the second blocking, the cells
were incubated with Alexa Fluor 488 chicken anti-mouse IgG
(Molecular Probes, Carlsbad, CA) at a working dilution of
10 mg/ml in the dark for an hr. The cells were then mounted to
a microslide with DAPI mounting media (Vector Laboratories,
Burlingame, CA) and analyzed under fluorescent microscopy
using the Axiovision software (Allied High Tech Products,
Rancho Dominguez, CA).
Rho A Activation Assay
The HUVEC and H28 cell lines were cultured in serum free
media treated with 10 mM lovastatin for 24 hrs with or without
100 mMm e v a l o n a t eo r1 0mM GGPP. Cells were stimulated
with 50 ng/ml EGF for 30 min to activate rhoA. Cell lysates
were either snap frozen and stored in liquid nitrogen or used
directly with the RhoA G-LISA kit (Cytoskeleton, Denver, Co)
according to the manufacturer’s instructions. This assay is based
on the principle that a Rho-GTP-binding protein is linked to the
96-well plates. The active GTP-bound Rho in the cell lysates
binds to the wells, while the inactive GDP-bound Rho is
removed during the washing steps. The bound active RhoA is
detected with a RhoA specific antibody and quantified by
absorbance. The degree of RhoA activation is determined by
comparing readings from the activated cell lysates (addition of
0.2 mM GTP) versus the non-activated cell lysates (serum
starved cultures).
Acknowledgments
Technical support from Melissa Morley is greatly appreciated. We wish to
thank Apotex Canada and the National Cancer Institute for generously
providing reagents used in this study.
Author Contributions
Conceived and designed the experiments: TTZ DT CA JD. Performed the
experiments: TTZ DT. Analyzed the data: TTZ JD. Wrote the paper:
TTZ DT CA JD.
Lovastatin Inhibits VEGFR
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12563References
1. Folkman J, Kalluri R (2004) Cancer without disease. Nature 427: 787.
2. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674.
3. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its
receptors. Nat Med 9: 669–676.
4. Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, et al. (2001)
Multiple forms of mouse vascular endothelial growth factor-D are generated by
RNA splicing and proteolysis. J Biol Chem 276: 44307–44314.
5. Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat
Rev Cancer 3: 859–868.
6. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC,
et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular
endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579–1586.
7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994)
Different signal transduction properties of KDR and Flt1, two receptors for
vascular endothelial growth factor. J Biol Chem 269: 26988–26995.
8. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival
functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:
777–794.
9. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, et al. (2001) Vascular
endothelial growth factor is an autocrine growth factor in human malignant
mesothelioma. J Pathol 193: 468–475.
10. Lee AY, Raz DJ, He B, Jablons DM (2007) Update on the molecular biology of
malignant mesothelioma. Cancer 109: 1454–1461.
11. Brenner J, Sordillo PP, Magill GB, Golbey RB (1982) Malignant mesothelioma
of the pleura: review of 123 patients. Cancer 49: 2431–2435.
12. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E (1999)
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and
TGF beta expression. J Pathol 189: 72–78.
13. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature
343: 425–430.
14. Gibbs JB, Oliff A, Kohl NE (1994) Farnesyltransferase inhibitors: Ras research
yields a potential cancer therapeutic. Cell 77: 175–178.
15. Sebti S, Hamilton AD (1997) Inhibitors of prenyl transferases. Curr Opin Oncol
9: 557–561.
16. Corsini A, Maggi FM, Catapano AL (1995) Pharmacology of competitive
inhibitors of HMG-CoA reductase. Pharmacological Research 31: 9–27.
17. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin
Cancer Res 9: 10–19.
18. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, et al. (2003)
Epidermal growth factor receptor-targeted therapy potentiates lovastatin-
induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer
Res Clin Oncol 129: 631–641.
19. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E (2002) Cholesterol is
important in control of EGF receptor kinase activity but EGF receptors are not
concentrated in caveolae. J Cell Sci 115: 1331–1340.
20. Slieker LJ, Martensen TM, Lane MD (1986) Synthesis of epidermal growth
factor receptor in human A431 cells. Glycosylation-dependent acquisition of
ligand binding activity occurs post-translationally in the endoplasmic reticulum.
J Biol Chem 261: 15233–15241.
21. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, et al. (2005)
Targeting the mevalonate pathway inhibits the function of the epidermal growth
factor receptor. Clin Cancer Res 11: 2398–2407.
22. Herbst RS (2002) ZD1839: targeting the epidermal growth factor receptor in
cancer therapy. Expert Opin Investig Drugs 11: 837–849.
23. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, et al. (2007) VEGF and
VEGFR-2 (KDR) internalization is required for endothelial recovery during
wound healing. Exp Cell Res 313: 1561–1574.
24. Lunn JA, Wong H, Rozengurt E, Walsh JH (2000) Requirement of cortical actin
organization for bombesin, endothelin, and EGF receptor internalization.
Am J Physiol Cell Physiol 279: C2019–2027.
25. Orth JD, Krueger EW, Weller SG, McNiven MA (2006) A novel endocytic
mechanism of epidermal growth factor receptor sequestration and internaliza-
tion. Cancer Res 66: 3603–3610.
26. Boulougouris P, Elder J (2001) Epidermal growth factor receptor structure,
regulation, mitogenic signalling and effects of activation. Anticancer Res 21:
2769–2775.
27. Crowell JA, Steele VE, Fay JR (2007) Targeting the AKT protein kinase for
cancer chemoprevention. Mol Cancer Ther 6: 2139–2148.
28. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, et al. (2005) A Phase I
trial of prolonged administration of lovastatin in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck or of the cervix.
Eur J Cancer 41: 523–530.
29. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, et al. (1996) Phase
I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with
cancer. Clin Cancer Res 2: 483–491.
30. Croft DR, Olson MF (2006) The Rho GTPase effector ROCK regulates cyclin
A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 26:
4612–4627.
31. Toschi A, Lee E, Xu L, Garcia A, Gadir N, et al. (2009) Regulation of
mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition
with rapamycin. Mol Cell Biol 29: 1411–1420.
32. Endo A, Fukuhara S, Masuda M, Ohmori T, Mochizuki N (2003) Selective
inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies
a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.
J Recept Signal Transduct Res 23: 239–254.
33. Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, et al.
(2004) KRN633: A selective inhibitor of vascular endothelial growth factor
receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol
Cancer Ther 3: 1639–1649.
34. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:
27–55.
35. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer
therapy. Oncogene 19: 6550–6565.
36. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, et al. (2003)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/
ZK 222584. Semin Oncol 30: 32–38.
37. Ramalingam SS, Belani CP (2008) Recent advances in the treatment of
malignant pleural mesothelioma. J Thorac Oncol 3: 1056–1064.
38. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, et al. (1999)
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis:
A potential therapeutic approach. Blood 93: 1308–1318.
39. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, et al. (2001)
Differential sensitivity of various pediatric cancers and squamous cell carcinomas
to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7:
158–167.
40. Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor
and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:
3602–3609.
41. Wang IK, Lin-Shiau SY, Lin JK (2000) Suppression of invasion and MMP-9
expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through
inhibition of ras isoprenylation. Oncology 59: 245–254.
42. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, et al. (2010)
Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell
carcinoma cells: potential regulation by targeting rho proteins. Oncogene.
43. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, et al. (1993)
Biotransformation of lovastatin. V. Species differences in in vivo metabolite
profiles of mouse, rat, dog, and human. Drug Metab Dispos 21: 1003–1011.
44. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, et al. (2006) Brain
cholesterol synthesis in mice is affected by high dose of simvastatin but not of
pravastatin. J Pharmacol Exp Ther 316: 1146–1152.
45. Wang CY, Shui HA, Chang TC (2010) In vivo evidence of duality effects for
lovastatin in a nude mouse cancer model. Int J Cancer 126: 578–582.
46. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005)
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:
123–132.
Lovastatin Inhibits VEGFR
PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12563